Germany
Alithea Bio, established in 2019, is a trailblazing company headquartered in Germany, operating at the intersection of biotech innovation and AI technology. Their slogan, "Precision medicine for immunotherapy," captures their mission of revolutionizing the immunotherapy landscape by leveraging advanced AI for target validation and off-target toxicity assessment.
Specializing in the characterization of HLA-presented peptides, Alithea Bio boasts the world's largest database for HLA peptide presentation, instrumental in improving biotherapeutics' safety and efficacy. Their proprietary SaaS platform, HLA-Compass, offers comprehensive tools for off-target safety evaluations and aids in cancer vaccine development with its NeoZoom pipeline.
The company's expertise in quantifying HLA peptides positions it as a crucial partner for biotech and pharmaceutical firms seeking to enhance their TCR and TCRm immunotherapy. Although Alithea Bio has not reported its last investment or investors, its distinctive offerings present compelling opportunities for venture capitalists aiming to invest in cutting-edge immunotherapy solutions.
